Investigator-Initiated Study Supports Potential of VS-6766 as Treatment for RAS Mutant Tumors
Investigator-Initiated Study Supports Potential of VS-6766 as Treatment for RAS Mutant Tumors Results from a study supported by Chugai Pharmaceutical Co. and published in The LANCET Oncology showed that VS-6766 (formerly known as CH5126766, CKI27 and RO5126766; Verastem Oncology*), a unique inhibitor of the RAF/MEK signaling pathway, with a specific dosing regimen of 4 mg […]
Read More